NASDAQ : KOD
Kodiak Sciences Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 100.4 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 6.30B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 6.03B |
| Enterprise Value | 5.96B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 62.72M |
| Shares Outstanding | 62.72M |
| Shares Change (YoY) | +9.97% |
| Shares Change (QoQ) | +1.24% |
| Owned by Insiders (%) | 6.29% |
| Owned by Institutions (%) | 71.03% |
| Float | 36.84M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 101.79 |
| P/TBV Ratio | 101.82 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 2.49 |
| Quick Ratio | 2.39 |
| Debt / Equity | 0.86 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -368.37% |
| Return on Assets (ROA) | -60.45% |
| Return on Invested Capital (ROIC) | -124.49% |
| Return on Capital Employed (ROCE) | -121.71% |
| Weighted Average Cost of Capital (WACC) | 15.32% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.72M |
| Employee Count | 141 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 2.04 |
| 52-Week Price Change | +445.10% |
| 50-Day Moving Average | 64.93 |
| 200-Day Moving Average | 42.45 |
| Relative Strength Index (RSI) | 65.92 |
| Average Volume (20 Days) | 1,126,503 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 8.50M |
| Short Previous Month | 9.38M |
| Short % of Shares Out | 13.55% |
| Short % of Float | 23.07% |
| Short Ratio (days to cover) | 2.38 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -248.33M |
| Pretax Income | -241.99M |
| Net Income | -241.99M |
| EBITDA | -230.98M |
| EBIT | -248.33M |
| Earnings Per Share (EPS) | -$4.18 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 125.90M |
| Total Debt | 52.76M |
| Net Cash | 73.15M |
| Net Cash Per Share | $1.17 |
| Equity (Book Value) | 61.10M |
| Book Value Per Share | 0.97 |
| Working Capital | 78.59M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -158.51M |
| Capital Expenditures | -1.40M |
| Depreciation & Amortization | 17.35M |
| Net Borrowing | n/a |
| Free Cash Flow | -159.90M |
| FCF Per Share | -$2.55 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -9.97% |
| Shareholder Yield | -9.97% |
| Earnings Yield | -4.34% |
| FCF Yield | -2.57% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $121.67 |
| Price Target Difference | 26.46% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |